The group with the higher number (n > 11) of CCL22 (+) cells had 12.5% (3/24) of cancer with lymph node metastasis, 83.3% (20/24) FIGO stage I to II, 70.8% (17/24) cases treated by surgery, and 37.5% (9/24) of cancer with death. The gene discussed is CCL22; the disease is metastatic malignant neoplasm in the lymph nodes.